UTI (NYSE: UTI) files Form 144 to sell 10,000 shares, $375K amount
Filing Impact
Filing Sentiment
Form Type
144
Rhea-AI Filing Summary
UTI submitted a Form 144 notice for the proposed sale of Common Stock, listing 10,000 shares and an aggregate amount of $375,000.00, dated 03/04/2026 on the NYSE.
The filing also lists stock awards dated 03/14/2022 for 5,246 shares and 02/22/2023 for 9,895 shares as securities to be sold.
Positive
- None.
Negative
- None.
Insights
Form 144 notifies the market of a planned sale of securities by an affiliate.
The notice lists 10,000 shares of Common Stock with an aggregate amount of $375,000.00 dated 03/04/2026. This is a regulatory disclosure under Rule 144 signaling an intended secondary sale.
Timing, method of sale, and whether sales will occur under volume limitations are not detailed here; subsequent transaction reports will show actual dispositions.
FAQ
What does UTI's Form 144 report?
The filing reports a proposed sale of Common Stock, listing 10,000 shares and an aggregate amount of $375,000.00 dated 03/04/2026. It identifies the securities as listed on the NYSE.
Which specific securities are listed to be sold on the Form 144?
The notice identifies Common Stock, $0.0001 par value and shows stock awards dated 03/14/2022 for 5,246 shares and 02/22/2023 for 9,895 shares as securities to be sold.
Does the Form 144 show recent sales in the past three months?
The provided excerpt includes a headed section for "Securities Sold During The Past 3 Months" but contains no listed sales in that section in the excerpt supplied. The filing therefore does not show recent three‑month sales here.
Who receives proceeds from the proposed sale in the Form 144?
The excerpt labels the transaction under "Issuer Information" and lists the securities and amounts, but it does not specify who will receive sale proceeds in the provided text. Proceeds treatment is not described in this excerpt.